3rd Annual MSK Symposium on LYMPHOMA
State-of-the-Art in Biology, Therapy and Patient Care

MAY 11-12, 2018 | NEW YORK CITY
This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.

EDUCATIONAL OBJECTIVES

• To provide up-to-date information on recent molecular diagnostic methods
• To provide up-to-date information on recent update on lymphoma pathology classification
• To provide up-to-date information on recent treatment options for patients with Hodgkin and non-Hodgkin lymphoma

TARGET AUDIENCE

The target audience includes medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.
INVITED FACULTY

Ash A. Alizadeh, MD, PhD
Stanford University
Stanford, CA

Marc André, MD
Université Catholique de Louvain
Belgium

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, Minnesota

Andreas Engert, MD
University Hospital of Cologne
Germany

Jude Fitzgibbon, PhD
Barts Cancer Institute
England

John P. Leonard, MD
Weill Cornell Medical College
New York, NY

Ronald Levy, MD
Stanford University
Stanford, CA

David Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Ari M. Melnick, MD
Weill Cornell Medical College
New York, NY

Franck Morschhauser, MD
Centre Hospitalier Régional Universitaire de Lille
France

Sattva S. Neelapu, MD
MD Anderson Cancer Center
Houston, Texas

Featuring
National and International Experts

Laura Pasqualucci, MD
Columbia University
New York, NY

Davide Rossi, MD, PhD
The Institute of Oncology Research
Switzerland

Stephen J. Schuster, MD
The University of Pennsylvania
Philadelphia, PA

John Seymour, MBBS, FRACP, PhD
Peter MacCallum Cancer Centre
Australia

Louis M. Staudt, MD, PhD
National Cancer Institute
Bethesda, MD

Catherine Thieblemont, MD
Saint-Louis Hospital
France

Irving Weissman, MD
Stanford University
Stanford, CA

Wyndham Wilson, MD, PhD
National Cancer Institute
Bethesda, MD

Thomas E. Witzig, MD
Mayo Clinic
Rochester, Minnesota

Weili Zhao, MD, PhD
Shanghai Institute of Hematology
China

SCIENTIFIC AGENDA

FRIDAY, MAY 11, 2018

REGISTRATION & BREAKFAST
7:30 AM

Department of Medicine Grand Rounds
Disrupting the CD47-SIRPα Anti-phagocytic Axis to Treat Cancer
Irving Weissman, MD
8:00 AM

BREAK
8:55 AM

Welcoming Remarks & State of the Lymphoma at MSK
Anas Younes, MD
9:00 AM

SESSION I
Advances and State of the Art in Clinical Care-1
MODERATOR
Andrew D. Zelenetz, MD, PhD
9:45 AM

Diffuse Large B Cell Lymphoma (DLBCL)
Andrew D. Zelenetz, MD, PhD
10:00 AM

T Cell Lymphoma
Steven M. Horwitz, MD
10:15 AM

Mantle Cell Lymphoma
John P. Leonard, MD
10:30 AM

MCL Trials at MSKCC
Anita Kumar, MD
10:45 AM

HIV Lymphoma
Ariela Noy, MD
11:00 AM

Panel Discussion
Session I Faculty
& John P. Leonard, MD
11:30 AM

BREAK
SESSION II
Advances and State of the Art in Clinical Care-2
MODERATOR
David J. Straus, MD
11:45 AM

Follicular Lymphoma (FL)
John Seymour, MBBS, FRACP, PhD
12:00 PM

Hodgkin Lymphoma (HL)
Andreas Engert, MD
12:15 PM

HL Trials at MSKCC
Alison J. Moskowitz, MD
12:30 PM

Marginal Zone Lymphoma
Catherine Thieblemont, MD
12:45 PM

Double Hit Lymphoma
Wyndham Wilson, MD, PhD
1:00 PM

Panel Discussion
Session II Faculty
& Marc André, MD
1:30 PM

LUNCH

Adult BMT Luncheon (1:30-2:15 PM) *
Are CARs Over Taking Transplant in Lymphoma

*Space is limited and RSVP is required during course registration.
### SESSION III  
**Biology**  
**MODERATOR:** Hans-Guido Wendel, MD  
**2:30 PM**  
**Identifying New Therapeutic Targets in Follicular Lymphoma**  
Hans-Guido Wendel, MD  
**2:45 PM**  
**Mechanism-based Therapy of DLBCL**  
Louis M. Staudt, MD, PhD  
**3:00 PM**  
**Epigenetic Evolution in Lymphoma**  
Ari M. Melnick, MD  
**3:15 PM**  
**Genetic Landscape of Follicular Lymphoma**  
Jude Fitzgibbon, PhD  
**3:30 PM**  
**Genetic Cooperation in Lymphomagenesis**  
Laura Pasqualucci, MD  
**3:45 PM**  
**Panel Discussion**  
Session III Faculty  
**4:00 PM**  
**BREAK**

### SESSION IV  
**Role of Radiation Therapy**  
**MODERATOR:** Joachim Yahalom, MD, FACR  
**4:15 PM**  
**Highlights of Modern Indications, Design and Technology**  
Joachim Yahalom, MD, FACR  
**4:30 PM**  
**Combining Immune Therapy with Radiation Therapy for NHL**  
M. Lia Paiomba, MD  
**4:45 PM**  
**When Do I Use Combined Modality Therapy in Early Stage HL**  
Marc André, MD  
**5:00 PM**  
**When Do I Use Combined Modality Therapy in DLBCL**  
Paul A. Hamlin, MD  
**5:15 PM**  
**Panel Discussion**  
Session IV Faculty, Andreas Engert, MD, & John Seymour, MBBS, FRACP, PhD,  
**5:30 PM**  
**Networking Cocktail Reception**  
**6:30 PM**  
**DAY 1 ADJOURN**

**#MSKLympomaCME**

---

### SESSION V  
**Clinical Application of Genome Sequencing**  
**MODERATOR:** Ahmet Dogan, MD, PhD  
**8:00 AM**  
**Introduction to Clinical Diagnostic Genome Sequencing**  
Maria E. Arcila, MD  
**8:30 AM**  
**Genome Sequencing and Outcome of Therapy in DLBCL**  
Weili Zhao, MD, PhD  
**8:45 AM**  
**Genome Sequencing of DLBCL Using Clinical Assays at Memorial Sloan Kettering**  
Erel Joffe, MD  
**9:00 AM**  
**Clinical Application of ctDNA in NHL**  
Ash A. Alizadeh, MD, PhD  
**9:15 AM**  
**Assessment of ctDNA in HL**  
Davide Rossi, MD, PhD  
**9:30 AM**  
**Panel Discussion**  
Session V Faculty  
**9:45 AM**  
**BREAK**

### SESSION VI  
**Focus on Precision Medicine: Master Protocol in Lymphoma (MasterLymph)**  
**MODERATOR:** Anas Younes, MD  
**10:00 AM**  
**Genomic Classification of DLBCL, Implications for Precision Medicine**  
Louis M. Staudt, MD, PhD  
**10:30 AM**  
**Biomarker Selection: Targeting EZH2**  
Franck Morschhauser, MD  
**10:45 PM**  
**Biomarker Selection: Combined HDAC and BCL2 Inhibitors**  
Connie Lee Batlevi, MD, PhD  
**11:00 AM**  
**Biomarker-driven Trials in Lymphoma: Histology-specific or Across Lymphoma Histologies**  
Thomas E. Witzig, MD  
**11:15 AM**  
**Immune Therapy in the Era of Precision Medicine**  
Ronald Levy, MD  
**11:30 AM**  
**Precision Medicine in the Era of Combination Therapy: Introduction to the MasterLymph Protocol**  
Anas Younes, MD  
**11:45 AM**  
**Panel Discussion**  
Session VI Faculty  
**12:15 PM**  
**LUNCH**  
**Myeloma Luncheon (12:15-1:00 PM)*  
**Genetic Characterization of Myeloma Cells and Reprogramming of T-cells: Modern Myeloma Treatment**  

*Space is limited and RSVP is required during course registration.
### SESSION VII
**Immune Therapy**

**MODERATOR:** M. Lia Palomba, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15</td>
<td>CAR T-cell: Transcend Study</td>
<td>David Maloney, MD, PhD</td>
</tr>
<tr>
<td>1:30</td>
<td>CAR T-cell: ZUMA-1 Study</td>
<td>Sattva S. Neelapu, MD</td>
</tr>
<tr>
<td>1:45</td>
<td>CAR T-cell: Juliet Study</td>
<td>Stephen J. Schuster, MD</td>
</tr>
<tr>
<td>2:00</td>
<td>New Approaches</td>
<td>Renier J. Brentjens, MD, PhD</td>
</tr>
<tr>
<td>2:15</td>
<td>Immune Checkpoint Inhibitors</td>
<td>Stephen M Ansell, MD, PhD</td>
</tr>
<tr>
<td>2:30</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>BREAK</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION VIII
**CNS Lymphoma**

**MODERATOR:** Paul A. Hamlin, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15</td>
<td>How I Treat CNS Lymphoma at the NCI</td>
<td>Wyndham Wilson, MD, PhD</td>
</tr>
<tr>
<td>3:30</td>
<td>How I Treat CNS Lymphoma at Memorial Sloan Kettering</td>
<td>Christian Grommes, MD</td>
</tr>
<tr>
<td>3:45</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### REGISTRATION FEES

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs and DOs)</td>
<td>$400</td>
</tr>
<tr>
<td>Nurses, PAs and Other Healthcare Professionals</td>
<td>$200</td>
</tr>
<tr>
<td>Residents and Fellows</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Professionals*</td>
<td>$700</td>
</tr>
</tbody>
</table>

*Industry professionals* may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

### Registration Online:

[mskcc.org/LymphomaCourse](http://mskcc.org/LymphomaCourse)

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary needs.

- **30% Discounted Rate for MSK Alumni and MSK Alliance Members:** MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for a promotion code or more information.
- **MSK Staff Registration:** Registration is complimentary for MSK staff. However, you must register online: [mskcc.org/LymphomaCourse](http://mskcc.org/LymphomaCourse)

### ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### AMA CREDIT DESIGNATION STATEMENT

MSK designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Attendees registered for the 3rd Annual MSK Symposium on Lymphoma (May 11-12) will receive a registration discount to attend:

MASTERCLASS IN
LYMPHOMA PATHOLOGY

MAY 12-13, 2018

This one and half day course will provide a comprehensive review of new entities and challenging areas in the new 2017 WHO Classification of Lymphoid Neoplasms using case-based examples. The course is designed as an interactive slide seminar using microscope based teaching and will be limited to 30 participants.